Paper Details

  1. Home
  2. Paper Details

Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.

Author: JóźwiakS, KotulskaK, SadowskiK, SchwartzR A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Tuberous sclerosis complex (TSC) is a genetic disorder that causes non-cancerous tumors in different parts of the body. Medications called mTOR inhibitors have been shown to be effective for treating specific tumors associated with TSC. This review examines research on whether these medications might have a broader effect on the disease itself, potentially improving outcomes for people with TSC.
Paper Details　
Original Abstract of the Article :
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder associated with constitutive overactivation of the mammalian target of rapamycin (mTOR) pathway and characterized by development of benign tumours in various organs. mTOR inhibitors have proven to be effective in the targeted therapy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jdv.13356

データ提供：米国国立医学図書館（NLM）

Tuberous Sclerosis Complex: A Journey Through the Desert of mTOR

Tuberous sclerosis complex (TSC) is a genetic disorder that can affect multiple organs, often resulting in the formation of benign tumors. This research delves into the complex interplay between mTOR, a key regulator of cellular growth, and TSC. The researchers investigate the systemic effects of mTOR inhibitors, drugs that target this pathway, in the treatment of TSC.

A Targeted Approach to Combatting TSC

The researchers highlight the potential of mTOR inhibitors as a targeted therapy for TSC. These drugs, like carefully crafted tools, can directly impact the mTOR pathway, potentially offering a more effective and less invasive treatment option for individuals with TSC.

Unraveling the Systemic Impact of mTOR Inhibition

This research sheds light on the complex systemic effects of mTOR inhibition in individuals with TSC. By understanding the multifaceted influence of these drugs, we can develop more personalized treatment strategies that address the unique challenges of TSC.

Dr.Camel's Conclusion

This research offers valuable insights into the potential benefits of mTOR inhibitors for treating TSC. By targeting this key pathway, these drugs may offer a more effective and targeted approach to managing this complex disorder.

Date :
  1. Date Completed 2016-12-27
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

26403211

DOI: Digital Object Identifier

10.1111/jdv.13356

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.